HCA HCA Healthcare, Inc. Common Stock
حول HCA Healthcare, Inc. Common Stock نظرة عامة على الشركة من ويكيبيديا
HCA Healthcare, Inc. is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors.
اقرأ المزيد
HCA Healthcare, Inc. (historically known as Hospital Corporation of America) is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors.
History
Early years
The Hospital Corporation of America (HCA) was founded in 1968 in Nashville, Tennessee, by Thomas F. Frist Sr., Thomas F. Frist Jr. and Jack C. Massey. The founders envisioned a company that would bring together hospitals to deliver patient-focused care while using the combined resources of the organization to strengthen hospitals and improve the practice of medicine. The company began with Nashville's Park View Hospital, which the elder Frist had founded in 1960 with other doctors and where he was serving as chief executive.
The company included 11 hospitals when it filed its initial public offering on the New York Stock Exchange (NYSE) in 1969 and had 26 hospitals and 3,000 beds by the end of the year.
Growth and merger
The 1970s were characterized by rapid growth in the industry and for HCA Healthcare. In the early 1980s, the focus shifted to consolidation with HCA Healthcare acquiring General Care Corporation, General Health Services, Hospital Affiliates International and Health Care Corporation. By the end of 1981, the company operated 349 hospitals with more than 49,000 beds. Operating revenues had grown to $2.4 billion.
In 1987, HCA Healthcare, which had grown to operate 463 hospitals (255 owned and 208 managed), spun off HealthTrust, a privately owned, 104-hospital company. Believing its stock was undervalued, the company completed a $5.1 billion leveraged management buyout led by chairman Thomas F. Frist Jr. in 1988. HCA Healthcare re-emerged as a public company in 1992.
In February 1994, HCA Healthcare merged with Louisville, Kentucky-based Columbia Hospital Corporation, which earlier had acquired 73 hospitals of Galen Health Care from Humana,
to form Columbia/HCA Healthcare Corporation. Related names of note include HCA International and Health Corporation of America.
Columbia Hospital Corporation
In 1988, Rick Scott and Richard Rainwater each put up $125,000 in working capital in their new company, Columbia Hospital Corporation; they borrowed the remaining money needed to purchase two struggling hospitals in El Paso for $60 million. Then they acquired a neighboring hospital and shut it down. Within a year, the remaining two were doing much better. By the end of 1989, Columbia Hospital Corporation owned four hospitals with a total of 833 beds.
In 1992, Columbia made a stock purchase of Basic American Medical, which owned eight hospitals, primarily in southwestern Florida. In September 1993, Columbia did another stock purchase, worth $3.4 billion, of Galen Healthcare, which had been spun off by Humana Inc. several months earlier. At the time, Galen had approximately 90 hospitals. After the purchase, Galen stockholders had 82% of the stock in the combined company, with Scott still running the company.
Recent history
On November 17, 2006, HCA became a private company for the third time when it completed a merger in which the company was acquired by a private investor group including affiliates of Kohlberg Kravis Roberts and Bain Capital, together with Merrill Lynch and HCA Healthcare founder Thomas F. Frist Jr. The total transaction was valued at approximately $33 billion, making it the largest leveraged buyout in history at the time, eclipsing the 1989 buyout of RJR Nabisco.
In May 2010, HCA announced that the corporation would once again go public with an expected $4.6-billion IPO as HCA Holdings, Inc. In March 2011, HCA sold 126.2 million shares for $30 each, raising about $3.79 billion, at that time, the largest private-equity backed IPO in U.S. history. In May 2017, the corporation was renamed HCA Healthcare.
In December 2018, a historical marker was installed in the parking lot of HCA's Sarah Cannon Cancer Center in Nashville, formerly the location of HCA's first hospital, Park View Hospital.
In 2018, the company was ranked No. 67 in the 2019 Fortune 500 list of the largest United States corporations by total revenue.
In May 2021, the company finalized a deal with Google to develop healthcare algorithms using patient records. In August 2021, HCA announced a deal with venture capital firm General Catalyst to develop digital solutions to streamline workflows and improve patient care; as part of the deal, HCA sold its healthcare app development firm PatientKeeper to General Catalyst's portfolio company Commure.
In April 2022, HCA Healthcare announced a $1.5 million partnership with Florida International University's Nicole Wertheim college of Nursing and Health Sciences, to expand its facilities to address the national nursing shortage.
In October 2022, LCMC Health in partnership with Tulane University announced that it would acquire Tulane Medical Center, Lakeview Regional Medical Center, and Tulane Lakeside Hospital from HCA for $150 million pending regulatory approval.
In March 2024, it was announced HCA had completed the sale of West Hills Hospital and Medical Center and related assets in Los Angeles, California to UCLA Health, for an undisclosed amount.
Facilities
United States
As of 2024, HCA has 186 hospitals. They also report operating more than 2,400 additional sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics located in 20 U.S. states and in the United Kingdom. A significant portion of those hospitals are situated in Florida and Texas. As of 2022, HCA had 47 hospitals and 31 surgery centers in Florida, and 45 hospitals and 632 affiliated sites of care in Texas. In 2021, it announced plans to build 3 new hospitals in Florida. In 2022, The Dallas Morning News reported that HCA will build 5 new hospitals in Texas. They also have a strong presence in Tennessee, where it began. HCA had 13 hospitals there as of 2019.
Between 2003 and 2017, HCA did not enter any new markets. However, in July 2007, HCA sold its hospitals in Switzerland.
In 2017, HCA acquired the Memorial University Medical Center in Savannah, Georgia. That same year, they acquired three Houston, Texas, hospitals from Tenet Healthcare.
In 2019 they purchased Mission Health System which operates hospitals in North Carolina.
In January 2020, HCA Healthcare acquired Valify, a healthcare cost-management company. In May 2020, HCA acquired 49-bed Shands Starke (Fla.) Regional Medical Center and 25-bed Shands Live Oak (Fla.) Regional Medical Center from CHS. HCA is operating the two facilities as off-campus emergency departments of Lake City (Fla.) Medical Center and North Florida Regional Medical Center in Gainesville. Later that year, it signed an agreement to sell Garden Park Medical Center to Singing River Health System.
In 2021, HCA sold Redmond Regional Medical Center to AdventHealth for $635M, and four other Georgia hospitals to Piedmont Healthcare for $950 million. They also announced the acquisition of Meadows Regional Medical Center.
United Kingdom
HCA International, the UK arm of Hospital Corporation of America, "caters for around half of all private patients in London." The main hospital sites within the United Kingdom it operates include:
It opened urgent care walk-in centres at London Bridge Hospital and the Portland Hospital in March 2018. It claims that patients, on average, wait just seven minutes to see a nurse and 17 minutes to see a doctor. In February 2022, outsourced cleaning staff at London Bridge Hospital reported a lack of PPE, no access to sick pay, a lack of training and no prior warning about which rooms may be contaminated with the virus through the COVID-19 pandemic.
The Princess Grace Hospital specializes in breast cancer and surgery, aided by Kefah Mokbel and Nick Perry who, in 2005, founded The London Breast Institute.
The company opened The Harborne Hospital, a newly built private hospital located close to the Queen Elizabeth Hospital, Birmingham, in February 2024.
Significant areas of operation
Medical education
In recent years, HCA Healthcare has become a significant provider of clinical and medical education. It is the largest sponsor of graduate medical education programs in the U.S., with 56 teaching hospitals in 14 states, primarily in regions with a deficit of physician training programs. The company includes Research College of Nursing and Mercy School of Nursing, and has several advanced nursing simulation training centers. In early 2020, it completed the purchase of a majority stake in Galen College of Nursing, which operates 21 campuses in 12 states, offering Bachelor of Science and Associate of Science nursing degrees.
Controversies
Medicare billing practices lawsuit
In 1993, lawsuits were filed against HCA by former employees who alleged that the company had engaged in questionable Medicare billing practices. In 1997, with a federal investigation by the FBI, the IRS and the Department of Health and Human Services in its early stages, the Columbia/HCA board of directors forced Rick Scott to resign as chairman and CEO amid growing evidence that the company "had kept two sets of books, one to show the government and one with actual expenses listed." Thomas Frist, a co-founder of HCA and brother of U.S. Senator Bill Frist, returned to the company as CEO in 1997 and called on longtime friend and colleague Jack O. Bovender Jr. to help him turn the company around.
The federal probe culminated in 2003 with "the government receiving a total of over $2 billion in criminal fines and civil penalties for systematically defrauding federal health care programs." Columbia/HCA pleaded guilty to 14 felonies and admitted to systematically overcharging the government. The federal probe has been referred to as the longest and costliest investigation for health-care fraud in U.S. history.
2005 insider trading suit
In July 2005, U.S. Senator Bill Frist sold all of his HCA shares, which were held in a blind trust, two weeks before disappointing earnings sent the stock on a 9-point plunge. At the time, Frist was considering a run for president and said that he had sold his shares to avoid the appearance of a conflict of interest. When the company disclosed that other executives had also sold their shares during that same time, shareholders alleged that the company had made false claims about its profits to drive up the price, which then fell when the company reported disappointing financial results. Eleven of HCA's senior officers were sued for accounting fraud and insider trading. HCA settled the lawsuit in August 2007, agreeing to pay $20 million to the shareholders but admitting no wrongdoing, and no charges were brought.
COVID-19 PPE
During the COVID-19 pandemic in the United States, HCA hospital nurses and other workers spoke out about the lack of PPE. In April 2020, there was an outcry against HCA following the deaths of two nurses Celia Yap-Banago and Rosa Luna who worked at HCA hospitals in Kansas City and California and had contracted coronavirus, despite the alarm having been raised about the lack of PPE at work.
Mission Hospital Acquisition Complaints
On December 14, 2023, the North Carolina Attorney General sued HCA for violating the terms of an agreement that allowed HCA to purchase Mission Health.
On February 13, 2024, HCA Healthcare denied the allegations and asked a judge to dismiss the lawsuit by the Attorney General, and in return the hospital network filed a counterclaim against the Attorney General.
المصدر: ويكيبيديا (الإنجليزية), CC BY-SA 4.0 · عرض على ويكيبيديا ↗
HCA لقطة سريعة للسهم السعر، القيمة السوقية، مكرر الربحية (P/E)، ربحية السهم (EPS)، العائد على حقوق الملكية (ROE)، نسبة الدين إلى حقوق الملكية، نطاق 52 أسبوعًا
HCA مخطط سعر السهم OHLCV يومي مع مؤشرات فنية — تحريك وتكبير وتخصيص عرضك
أداء 10 سنوات اتجاهات الإيرادات وصافي الدخل والهوامش وربحية السهم
التقييم نسب مكرر الربحية (P/E)، مكرر المبيعات (P/S)، مكرر القيمة الدفترية (P/B)، EV/EBITDA — هل السهم مرتفع السعر أم رخيص؟
الربحية هامش الربح الإجمالي والتشغيلي والصافي؛ العائد على حقوق الملكية (ROE)، العائد على الأصول (ROA)، العائد على رأس المال المستثمر (ROIC)
الصحة المالية الديون، السيولة، الملاءة المالية — قوة الميزانية العمومية
النمو نمو الإيرادات وربحية السهم وصافي الدخل: مقارنة بالعام السابق (YoY)، متوسط النمو السنوي المركب لـ 3 سنوات (3Y CAGR)، متوسط النمو السنوي المركب لـ 5 سنوات (5Y CAGR)
كفاءة رأس المال معدل دوران الأصول، معدل دوران المخزون، معدل دوران المستحقات
التوزيعات العائد، نسبة التوزيع، تاريخ توزيع الأرباح، معدل النمو السنوي المركب لمدة 5 سنوات
| تاريخ الاستحقاق | المبلغ |
|---|---|
| 16 يونيو، 2026 | $0,7800 |
| 17 مارس، 2026 | $0,7800 |
| 15 ديسمبر، 2025 | $0,7200 |
| 16 سبتمبر، 2025 | $0,7200 |
| 16 يونيو، 2025 | $0,7200 |
| 17 مارس، 2025 | $0,7200 |
| 13 ديسمبر، 2024 | $0,6600 |
| 16 سبتمبر، 2024 | $0,6600 |
| 14 يونيو، 2024 | $0,6600 |
| 14 مارس، 2024 | $0,6600 |
| 13 ديسمبر، 2023 | $0,6000 |
| 14 سبتمبر، 2023 | $0,6000 |
| 15 يونيو، 2023 | $0,6000 |
| 16 مارس، 2023 | $0,6000 |
| 13 ديسمبر، 2022 | $0,5600 |
| 15 سبتمبر، 2022 | $0,5600 |
| 15 يونيو، 2022 | $0,5600 |
| 16 مارس، 2022 | $0,5600 |
| 13 ديسمبر، 2021 | $0,4800 |
| 15 سبتمبر، 2021 | $0,4800 |
HCA توافق الآراء التحليلي آراء المحللين الصعودية والهبوطية، السعر المستهدف لمدة 12 شهرًا، الصعود
- شراء قوي 6 20,0%
- شراء 11 36,7%
- احتفاظ 12 40,0%
- بيع 1 3,3%
- بيع قوي 0 0,0%
السعر المستهدف لمدة 12 شهرًا
21 محللين · 2026-08-17سجل الأرباح ربحية السهم الفعلية مقابل التقديرات، نسبة المفاجأة %، معدل التجاوز، تاريخ الأرباح التالي
| الفترة | EPS Actual | EPS المتوقع | المفاجأة |
|---|---|---|---|
| 30 يونيو، 2026 | $7.62 | $7.54 | 0.08% |
| 31 مارس، 2026 | $7.15 | $7.21 | -0.06% |
| 31 ديسمبر، 2025 | $8.14 | $7.53 | 0.61% |
| 30 سبتمبر، 2025 | $6.96 | $5.77 | 1.2% |
| 30 يونيو، 2025 | $6.83 | $6.31 | 0.52% |
| 31 مارس، 2025 | $6.45 | $5.84 | 0.61% |
مقارنة الأقران (الصناعة الفرعية GICS) المقاييس الرئيسية مقابل أقران القطاع
| الرمز | القيمة السوقية | P/E | الإيرادات سنويًا | هامش الربح الصافي | ROE | هامش الربح الإجمالي |
|---|---|---|---|---|---|---|
| HCA | $104.86B | 16.5 | 7.1% | 9.0% | -159.1% | — |
| THC | $17.28B | 12.8 | 3.1% | 11.1% | 56.4% | — |
| EHC | $10.61B | 19.2 | 10.5% | 9.5% | 25.1% | — |
| ENSG | $10.12B | 29.8 | 18.7% | 6.8% | 16.9% | — |
| UHS | — | 9.4 | 9.7% | 8.6% | 21.4% | — |
| PACS | $6.01B | 31.5 | 29.3% | 3.6% | 23.1% | — |
| CON | $2.53B | 15.1 | 13.9% | 7.7% | 49.8% | — |
| BKD | $2.57B | -9.6 | 2.2% | -8.2% | -313.2% | 26.2% |
| ACHC | $1.28B | -1.2 | 5.0% | -33.3% | -43.9% | — |
| SGRY | $2.00B | -25.3 | 6.2% | -2.4% | -4.5% | — |
الأساسيات الكاملة جميع المقاييس حسب السنة — قائمة الدخل، الميزانية العمومية، التدفق النقدي
قائمة الدخل 12
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| SG&A Expense | $548M | $421M | $353M | $307M | $337M | $416M | $370M | $344M | $340M | $343M | |
| Operating Expenses | $65.77B | $62.08B | $57.26B | $51.65B | $48.92B | $46.10B | $46.09B | $41.34B | $39.23B | $36.68B | |
| Interest Expense | $2.25B | $2.06B | $1.94B | $1.74B | $1.57B | $1.58B | $1.82B | $1.75B | $1.69B | $1.71B | |
| Pretax Income | $9.83B | $8.52B | $7.71B | $8.58B | $9.83B | $5.43B | $5.24B | $5.33B | $4.38B | $4.81B | |
| Income Tax | $2.05B | $1.87B | $1.61B | $1.75B | $2.11B | $1.04B | $1.10B | $946M | $1.64B | $1.38B | |
| Net Income | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| EPS (Basic) | $28.70 | $22.27 | $19.25 | $19.43 | $21.52 | $11.10 | $10.27 | $10.90 | $6.12 | $7.53 | |
| EPS (Diluted) | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 | $10.93 | $10.07 | $10.66 | $5.95 | $7.30 | |
| Shares (Basic) | 236,413,000 | 258,603,000 | 272,404,000 | 290,348,000 | 323,315,000 | 338,274,000 | 341,210,000 | 347,297,000 | 362,305,000 | 383,591,000 | |
| Shares (Diluted) | 239,495,000 | 261,806,000 | 276,412,000 | 294,666,000 | 328,752,000 | 343,605,000 | 348,226,000 | 355,303,000 | 372,221,000 | 395,851,000 | |
| EBITDA | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B |
الميزانية العمومية 22
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.04B | $1.93B | $935M | $908M | $1.45B | $1.79B | $621M | $502M | $732M | $646M | |
| Short-term Investments | · | · | · | · | · | $116M | $147M | $47M | $54M | $49M | |
| Receivables | $10.87B | $10.75B | $9.96B | $8.89B | $8.10B | $7.05B | $7.38B | $6.79B | $6.50B | $5.83B | |
| Inventory | $1.65B | $1.74B | $2.02B | $2.07B | $1.99B | $2.02B | $1.85B | $1.73B | $1.57B | $1.50B | |
| Other Current Assets | $2.22B | $1.99B | $2.01B | $1.78B | $2.01B | $1.46B | $1.35B | $1.19B | $1.17B | $1.11B | |
| Current Assets | $15.78B | $16.41B | $14.93B | $13.64B | $13.54B | $12.33B | $11.20B | $10.21B | $9.98B | $9.09B | |
| PP&E (Net) | $31.14B | $29.41B | $27.71B | $25.57B | $24.06B | $23.20B | $22.71B | $19.76B | $17.89B | $16.35B | |
| PP&E (Gross) | $66.28B | $62.51B | $58.55B | $54.76B | $51.35B | $49.32B | $47.23B | $42.97B | $40.08B | $37.05B | |
| Accum. Depreciation | $35.13B | $33.10B | $30.83B | $29.18B | $27.29B | $26.12B | $24.52B | $23.21B | $22.19B | $20.70B | |
| Other Non-current Assets | $255M | $230M | $184M | $298M | $598M | $546M | $480M | $690M | $710M | $1.07B | |
| Total Assets | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Accounts Payable | $4.66B | $4.28B | $4.23B | $4.24B | $4.11B | $3.54B | $2.90B | $2.58B | $2.61B | $2.32B | |
| Current Liabilities | $16.35B | $15.18B | $12.65B | $9.90B | $9.58B | $8.70B | $7.76B | $7.57B | $6.16B | $5.83B | |
| Capital Leases | $1.85B | $1.86B | $1.90B | $1.75B | $1.75B | $1.67B | $1.50B | · | · | · | |
| Total Liabilities | · | · | · | · | · | · | $45.62B | $42.12B | $41.59B | $39.39B | |
| Long-term Debt | $44.28B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Total Debt | $41.60B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Retained Earnings | $-5.72B | $-2.12B | $-1.35B | $-2.28B | $-532M | $777M | $-2.35B | $-4.57B | $-6.53B | $-6.97B | |
| AOCI | $-305M | $-387M | $-425M | $-490M | $-404M | $-502M | $-460M | $-381M | $-278M | $-338M | |
| Stockholders' Equity | $-6.03B | $-2.50B | $-1.77B | $-2.77B | $-933M | $572M | $-2.81B | $-4.95B | $-6.81B | $-7.30B | |
| Liabilities + Equity | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Shares Outstanding | 224,605,100 | 249,981,400 | 265,537,300 | 277,378,300 | 305,476,800 | 339,425,600 | 338,445,600 | 342,895,200 | 350,091,600 | 370,535,900 |
التدفق النقدي 17
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B | |
| Stock-based Comp | $401M | $360M | $262M | $341M | $440M | $362M | $347M | $268M | $270M | $251M | |
| Amort. of Intangibles | $12M | $16M | $20M | $44M | $25M | $26M | · | · | · | · | |
| Other Non-cash | $1.93B | $1.08B | $850M | $-431M | $-1.29B | $2.40B | $1.07B | $461M | $-3.53B | $-2.67B | |
| Operating Cash Flow | $12.64B | $10.51B | $9.43B | $8.52B | $8.96B | $9.23B | $7.60B | $6.76B | $5.43B | $5.65B | |
| CapEx | $4.94B | $4.88B | $4.74B | $4.39B | $3.58B | $2.83B | $4.16B | $3.57B | $3.02B | $2.76B | |
| Investing Cash Flow | $-4.99B | $-4.93B | $-5.32B | $-3.39B | $-2.64B | $-3.39B | $-5.72B | $-3.90B | $-4.28B | $-3.24B | |
| Debt Issued | $8.47B | $7.50B | $3.22B | $6.00B | $4.34B | $2.70B | $6.45B | $2.00B | $1.50B | $5.40B | |
| Net Debt Issued | $1.08B | $5.08B | $2.31B | $3.17B | $475M | $-737M | $1.13B | $296M | $749M | $925M | |
| Stock Repurchased | $10.07B | $6.04B | $3.81B | $7.00B | $8.21B | $441M | $1.03B | $1.53B | $2.05B | $2.75B | |
| Net Stock Activity | $-10.07B | $-6.04B | $-3.81B | $-7.00B | $-8.21B | $-441M | $-1.03B | $-1.53B | $-2.05B | $-2.75B | |
| Dividends Paid | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · | |
| Financing Cash Flow | $-8.55B | $-4.58B | $-4.09B | $-5.66B | $-6.66B | $-4.68B | $-1.77B | $-3.08B | $-1.06B | $-2.51B | |
| Net Change in Cash | $-893M | $998M | $27M | $-543M | $-342M | $1.17B | $119M | $-230M | $86M | $-95M | |
| Taxes Paid | $1.74B | $1.84B | $1.39B | $1.18B | $2.18B | $1.00B | $849M | $872M | $1.21B | $1.25B | |
| Free Cash Flow | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B | $6.40B | $3.44B | $3.19B | $2.41B | $2.89B | |
| Levered FCF | $5.91B | $4.03B | $3.16B | $2.74B | $4.15B | $5.12B | $2.00B | $1.74B | $1.35B | $1.68B |
الربحية 5
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 9.0% | 8.2% | 8.1% | 9.4% | 11.8% | 7.3% | 6.8% | 8.1% | · | · | |
| Pretax Margin | 13.0% | 12.1% | 11.9% | 14.2% | 16.7% | 10.5% | 10.2% | 11.4% | · | · | |
| EBITDA Margin | 4.7% | 4.7% | 4.7% | 4.9% | 4.9% | 5.3% | 5.1% | 4.9% | · | · | |
| ROA | 11.3% | 10.0% | 9.7% | 10.9% | 14.2% | 8.1% | 8.3% | 10.0% | 6.3% | 8.7% | |
| ROE | -159.1% | -269.6% | -230.9% | -305.0% | -3853.7% | -335.8% | -90.4% | -64.4% | -31.4% | -38.8% |
السيولة والملاءة 4
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 | 1.4 | 1.4 | 1.3 | 1.6 | 1.6 | |
| Quick Ratio | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 | 1.0 | 1.1 | 1.0 | 1.2 | 1.1 | |
| Debt / Equity | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 | 54.2 | -12.0 | -6.6 | -4.9 | -4.3 | |
| LT Debt / Equity | -6.9 | -15.3 | -21.0 | -13.6 | -36.8 | 53.8 | -12.0 | -6.5 | -4.8 | -4.3 |
الكفاءة 2
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.3 | 1.2 | 1.2 | 1.2 | 1.2 | 1.1 | 1.2 | 1.2 | · | · | |
| Receivables Turnover | 7.0 | 6.8 | 6.9 | 7.1 | 7.8 | 7.1 | 7.2 | 7.0 | · | · |
معدلات النمو 10
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 7.1% | 8.7% | 7.9% | 2.5% | 14.0% | · | · | · | · | · | |
| Revenue CAGR 3Y | 7.9% | 6.3% | 8.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 8.0% | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 28.8% | 16.0% | -0.94% | -9.5% | 93.6% | · | · | · | · | · | |
| EPS CAGR 3Y | 13.9% | 1.3% | 20.2% | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 21.0% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 17.8% | 9.9% | -7.1% | -18.9% | 85.3% | · | · | · | · | · | |
| Net Income CAGR 3Y | 6.3% | -6.1% | 11.8% | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 12.6% | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 34.7% | · | · | · | · | · | · | · | · | · |
التقييم (آخر 12 شهرًا) 17
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| Net Income TTM | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| Market Cap | $104.86B | $75.03B | $71.88B | $66.56B | $78.48B | $55.82B | $50.03B | $42.67B | $30.75B | $27.43B | |
| Enterprise Value | $145.42B | $116.13B | $110.53B | $103.74B | $111.61B | $84.92B | $82.98B | $74.95B | $63.02B | $58.11B | |
| P/E | 16.5 | 13.6 | 14.3 | 12.5 | 12.1 | 15.0 | 14.7 | 11.7 | 14.8 | 10.1 | |
| P/S | 1.4 | 1.1 | 1.1 | 1.1 | 1.3 | 1.1 | 1.0 | 0.9 | 0.7 | 0.7 | |
| P/B | -17.4 | -30.0 | -40.5 | -24.1 | -84.1 | 97.6 | -17.8 | -8.6 | -4.5 | -3.8 | |
| P / Tangible Book | · | · | · | · | · | 97.6 | · | · | · | · | |
| P / Cash Flow | 8.3 | 7.1 | 7.6 | 7.8 | 8.8 | 6.0 | 6.6 | 6.3 | 5.7 | 4.9 | |
| P / FCF | 13.6 | 13.3 | 15.3 | 16.1 | 14.6 | 8.7 | 14.5 | 13.4 | 12.8 | 9.5 | |
| EV / EBITDA | 41.3 | 35.1 | 35.9 | 34.9 | 39.1 | 31.2 | 32.0 | 32.9 | 29.6 | 29.6 | |
| EV / FCF | 18.9 | 20.6 | 23.6 | 25.1 | 20.7 | 13.3 | 24.1 | 23.5 | 26.1 | 20.1 | |
| EV / Revenue | 1.9 | 1.6 | 1.7 | 1.7 | 1.9 | 1.6 | 1.6 | 1.6 | 1.4 | 1.4 | |
| Dividend Yield | 0.65% | 0.92% | 0.92% | 0.98% | 0.80% | 0.27% | 1.1% | 1.1% | 0.00% | · | |
| Earnings Yield | 6.1% | 7.3% | 7.0% | 8.0% | 8.2% | 6.7% | 6.8% | 8.6% | 6.8% | 9.9% | |
| Payout Ratio | 10.0% | 12.0% | 12.6% | 11.6% | 9.0% | 4.1% | 15.7% | 12.9% | · | · | |
| Annual Payout | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · |
قائمة الدخل 12
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.23B | $19.11B | $19.51B | $19.16B | $18.61B | $18.32B | $18.29B | $17.49B | $17.49B | $17.34B | $17.30B | $16.21B | $15.86B | $15.59B | $15.50B | $14.97B | |
| SG&A Expense | $148M | $133M | $153M | $139M | $130M | $126M | $120M | $111M | $100M | $90M | $108M | $89M | $82M | $74M | $79M | $74M | |
| Operating Expenses | $17.74B | $16.82B | $16.84B | $16.74B | $16.19B | $15.99B | $16.15B | $15.58B | $15.26B | $15.09B | $14.96B | $14.58B | $14.05B | $13.67B | $12.20B | $13.27B | |
| Interest Expense | $599M | $584M | $572M | $561M | $568M | $547M | $528M | $515M | $506M | $512M | $491M | $483M | $485M | $479M | $453M | $446M | |
| Pretax Income | $2.49B | $2.29B | $2.67B | $2.42B | $2.42B | $2.33B | $2.13B | $1.91B | $2.24B | $2.25B | $2.35B | $1.63B | $1.81B | $1.92B | $3.30B | $1.70B | |
| Income Tax | $564M | $430M | $509M | $515M | $524M | $502M | $447M | $424M | $550M | $445M | $484M | $355M | $397M | $379M | $656M | $360M | |
| Net Income | $1.70B | $1.62B | $1.88B | $1.64B | $1.65B | $1.61B | $1.44B | $1.27B | $1.46B | $1.59B | $1.61B | $1.08B | $1.19B | $1.36B | $2.08B | $1.13B | |
| EPS (Basic) | $7.70 | $7.25 | $8.22 | $7.05 | $6.91 | $6.52 | $5.72 | $4.94 | $5.60 | $6.01 | $6.00 | $3.98 | $4.35 | $4.92 | $7.30 | $3.97 | |
| EPS (Diluted) | $7.62 | $7.15 | $8.09 | $6.96 | $6.83 | $6.45 | $5.66 | $4.88 | $5.53 | $5.93 | $5.92 | $3.91 | $4.29 | $4.85 | $7.20 | $3.91 | |
| Shares (Basic) | 220,538,000 | 223,588,000 | -482,587,000 | 232,891,000 | 239,173,000 | 246,936,000 | -523,751,000 | 256,763,000 | 261,156,000 | 264,435,000 | -550,173,000 | 271,173,000 | 274,494,000 | 276,910,000 | -590,583,000 | 285,958,000 | |
| Shares (Diluted) | 222,828,000 | 226,652,000 | -488,037,000 | 236,181,000 | 241,911,000 | 249,440,000 | -530,198,000 | 259,917,000 | 264,071,000 | 268,016,000 | -558,171,000 | 275,424,000 | 278,198,000 | 280,961,000 | -598,621,000 | 289,852,000 | |
| EBITDA | $944M | $930M | · | $889M | $863M | $860M | · | $842M | $819M | $795M | · | $769M | $763M | $756M | · | $749M |
الميزانية العمومية 20
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.01B | $940M | $1.04B | $997M | $939M | $1.06B | $1.93B | $2.89B | $831M | $1.28B | · | $891M | $862M | $842M | · | $999M | |
| Receivables | $12.28B | $11.32B | $10.87B | $10.43B | $10.46B | $11.09B | $10.75B | $9.91B | $10.24B | $10.04B | · | $9.18B | $8.71B | $8.66B | · | $8.55B | |
| Inventory | $1.66B | $1.68B | $1.65B | $1.73B | $1.79B | $1.79B | $1.74B | $1.78B | $1.80B | $1.90B | · | $2.03B | $2.05B | $2.08B | · | $2.01B | |
| Other Current Assets | $2.23B | $2.11B | $2.22B | $2.13B | $2.37B | $2.32B | $1.99B | $2.08B | $2.30B | $2.05B | · | $2.19B | $2.26B | $1.96B | · | $1.92B | |
| Current Assets | $17.19B | $16.05B | $15.78B | $15.29B | $15.56B | $16.26B | $16.41B | $16.66B | $15.17B | $15.28B | · | $14.29B | $13.89B | $13.54B | · | $13.48B | |
| PP&E (Net) | $31.82B | $31.47B | $31.14B | $30.57B | $30.12B | $29.74B | $29.41B | $29.05B | $28.64B | $28.10B | · | $27.12B | $26.64B | $26.05B | · | $24.98B | |
| PP&E (Gross) | $68.41B | $67.36B | $66.28B | $65.49B | $64.39B | $63.68B | $62.51B | $61.75B | $60.62B | $59.44B | · | $57.77B | $56.67B | $55.46B | · | $53.73B | |
| Accum. Depreciation | $36.59B | $35.89B | $35.13B | $34.92B | $34.27B | $33.94B | $33.10B | $32.70B | $31.99B | $31.34B | · | $30.66B | $30.02B | $29.41B | · | $28.75B | |
| Other Non-current Assets | $258M | $326M | $255M | $277M | $236M | $226M | $230M | $309M | $240M | $199M | · | $200M | $196M | $319M | · | $461M | |
| Total Assets | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | $56.21B | $54.59B | $53.59B | $52.71B | $52.44B | $51.48B | |
| Accounts Payable | $4.75B | $4.81B | $4.66B | $4.55B | $4.25B | $4.49B | $4.28B | $4.24B | $4.03B | $4.74B | · | $4.14B | $3.82B | $3.77B | · | $4.16B | |
| Current Liabilities | $17.31B | $19.26B | $16.35B | $17.90B | $15.94B | $13.63B | $15.18B | $14.90B | $14.30B | $13.14B | · | $12.41B | $11.54B | $11.03B | · | $9.78B | |
| Capital Leases | $1.83B | $1.82B | $1.85B | $1.84B | $1.88B | $1.86B | $1.86B | $1.92B | $1.89B | $1.91B | · | $1.78B | $1.81B | $1.72B | · | $1.76B | |
| Long-term Debt | $45.83B | $44.37B | $44.28B | $42.60B | $42.70B | $44.58B | $43.03B | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Total Debt | $43.45B | $39.49B | · | $38.40B | $39.38B | $44.58B | · | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Retained Earnings | $-6.31B | $-5.98B | $-5.72B | $-5.02B | $-4.09B | $-3.16B | $-2.12B | $-1.81B | $-1.17B | $-1.19B | · | $-1.99B | $-1.85B | $-2.03B | · | $-2.78B | |
| AOCI | $-334M | $-327M | $-305M | $-317M | $-309M | $-357M | $-387M | $-378M | $-433M | $-433M | $-425M | $-491M | $-456M | $-470M | $-490M | $-592M | |
| Stockholders' Equity | $-6.64B | $-6.30B | $-6.03B | $-5.33B | $-4.39B | $-3.52B | $-2.50B | $-2.18B | $-1.60B | $-1.61B | · | $-2.48B | $-2.30B | $-2.50B | · | $-3.37B | |
| Liabilities + Equity | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | · | $54.59B | $53.59B | $52.71B | · | $51.48B | |
| Shares Outstanding | 217,963,300 | 222,530,900 | 224,605,100 | 229,845,100 | 236,143,900 | 242,955,400 | 249,981,400 | 254,517,700 | 259,237,600 | 263,215,800 | · | 268,967,300 | 272,931,700 | 275,939,900 | · | 283,903,500 |
التدفق النقدي 16
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $944M | $930M | $911M | $889M | $863M | $860M | $856M | $842M | $819M | $795M | $789M | $769M | $763M | $756M | $750M | $749M | |
| Stock-based Comp | $85M | $86M | $100M | $104M | $99M | $98M | $85M | $76M | $112M | $87M | $57M | $72M | $56M | $77M | $83M | $87M | |
| Other Non-cash | · | $-622M | · | · | · | $-917M | · | · | · | $-4M | · | · | · | $-393M | · | · | |
| Operating Cash Flow | $2.33B | $2.01B | $2.36B | $4.42B | $4.21B | $1.65B | $2.56B | $3.52B | $1.97B | $2.47B | $2.67B | $2.48B | $2.48B | $1.80B | $2.53B | $3.02B | |
| CapEx | $1.23B | $1.12B | $1.49B | $1.29B | $1.18B | $991M | $1.28B | $1.19B | $1.28B | $1.12B | $1.16B | $1.15B | $1.24B | $1.20B | $1.32B | $1.13B | |
| Investing Cash Flow | $-1.56B | $-1.28B | $-1.32B | $-1.39B | $-1.25B | $-1.03B | $-1.35B | $-1.35B | $-1.33B | $-903M | $-1.60B | $-1.31B | $-1.26B | $-1.15B | $-793M | $-546M | |
| Debt Issued | $2.99B | $0 | $3.24B | $0 | $0 | $5.23B | $0 | $3.01B | $0 | $4.48B | $4M | $2M | $3.22B | $0 | $21M | $10M | |
| Net Debt Issued | · | $-58M | · | · | · | $1.34B | · | · | · | $2.42B | · | · | · | $-550M | · | · | |
| Stock Repurchased | $2.06B | $1.57B | $2.56B | $2.50B | $2.50B | $2.51B | $1.70B | $1.79B | $1.37B | $1.18B | $910M | $1.14B | $915M | $846M | $1.52B | $698M | |
| Net Stock Activity | · | $-1.57B | · | · | · | $-2.51B | · | · | · | $-1.18B | · | · | · | $-846M | · | · | |
| Dividends Paid | $171M | $183M | $162M | $166M | $171M | $180M | $165M | $169M | $171M | $185M | $160M | $162M | $164M | $175M | $156M | $160M | |
| Financing Cash Flow | $-704M | $-830M | $-999M | $-2.97B | $-3.09B | $-1.50B | $-2.16B | $-110M | $-1.09B | $-1.22B | $-1.04B | $-1.13B | $-1.20B | $-725M | $-1.84B | $-2.32B | |
| Net Change in Cash | $73M | $-100M | $43M | $58M | $-121M | $-873M | $-955M | $2.06B | $-453M | $349M | $44M | $29M | $20M | $-66M | $-91M | $141M | |
| Taxes Paid | $730M | $-5M | $1.51B | $81M | $136M | $10M | $358M | $487M | $998M | $1M | $316M | $297M | $766M | $7M | $244M | $322M | |
| Free Cash Flow | · | $895M | · | · | · | $660M | · | · | · | $1.35B | · | · | · | $606M | · | · | |
| Levered FCF | · | $421M | · | · | · | $231M | · | · | · | $940M | · | · | · | $221M | · | · |
الربحية 5
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 8.4% | 8.5% | · | 8.6% | 8.9% | 8.8% | · | 7.3% | 8.3% | 9.2% | · | 6.7% | 7.5% | 8.7% | · | 7.6% | |
| Pretax Margin | 12.3% | 12.0% | · | 12.6% | 13.0% | 12.7% | · | 10.9% | 12.8% | 13.0% | · | 10.1% | 11.4% | 12.3% | · | 11.4% | |
| EBITDA Margin | 4.7% | 4.9% | · | 4.6% | 4.6% | 4.7% | · | 4.8% | 4.7% | 4.6% | · | 4.7% | 4.8% | 4.9% | · | 5.0% | |
| ROA | 2.8% | 2.7% | · | 2.8% | 2.8% | 2.8% | · | 2.2% | 2.6% | 2.9% | · | 2.0% | 2.3% | 2.6% | · | 2.2% | |
| ROE | -30.8% | -33.0% | · | -43.7% | -55.2% | -62.7% | · | -54.5% | -74.9% | -77.4% | · | -36.9% | -39.9% | -60.2% | · | -55.8% |
السيولة والملاءة 4
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 0.8 | · | 0.9 | 1.0 | 1.2 | · | 1.1 | 1.1 | 1.2 | · | 1.2 | 1.2 | 1.2 | · | 1.4 | |
| Quick Ratio | 0.8 | 0.6 | · | 0.6 | 0.7 | 0.9 | · | 0.9 | 0.8 | 0.9 | · | 0.8 | 0.8 | 0.9 | · | 1.0 | |
| Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -12.7 | · | -19.7 | -25.6 | -24.9 | · | -15.9 | -16.9 | -15.6 | · | -11.2 | |
| LT Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -11.7 | · | -17.5 | -22.7 | -23.0 | · | -14.9 | -15.9 | -14.6 | · | -11.1 |
الكفاءة 2
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | |
| Receivables Turnover | 1.8 | 1.7 | · | 1.9 | 1.8 | 1.7 | · | 1.8 | 1.8 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
التقييم (آخر 12 شهرًا) 14
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $77.11B | $75.20B | · | $73.57B | $71.91B | $70.64B | · | $68.53B | $66.91B | $65.00B | · | $62.64B | $61.24B | $60.33B | · | $60.01B | |
| Net Income TTM | $6.62B | $6.53B | · | $6.18B | $5.99B | $5.93B | · | $5.40B | $5.32B | $5.23B | · | $4.77B | $4.84B | $4.92B | · | $5.83B | |
| Market Cap | $84.98B | $105.31B | · | $97.96B | $90.47B | $83.95B | · | $103.44B | $83.29B | $87.79B | · | $66.16B | $82.83B | $72.76B | · | $52.18B | |
| Enterprise Value | $127.42B | $143.86B | · | $135.36B | $128.91B | $127.47B | · | $143.52B | $123.34B | $126.70B | · | $104.62B | $120.90B | $110.77B | · | $88.89B | |
| P/E | 13.7 | 17.3 | · | 17.0 | 16.2 | 15.2 | · | 20.1 | 16.3 | 17.6 | · | 14.5 | 17.9 | 15.7 | · | 9.7 | |
| P/S | 1.1 | 1.4 | · | 1.3 | 1.3 | 1.2 | · | 1.5 | 1.2 | 1.4 | · | 1.1 | 1.4 | 1.2 | · | 0.9 | |
| P/B | -12.8 | -16.7 | · | -18.4 | -20.6 | -23.9 | · | -47.4 | -52.1 | -54.4 | · | -26.7 | -36.0 | -29.2 | · | -15.5 | |
| P / Cash Flow | · | 52.3 | · | · | · | 50.8 | · | · | · | 35.6 | · | · | · | 40.4 | · | · | |
| P / FCF | · | 117.7 | · | · | · | 127.2 | · | · | · | 65.0 | · | · | · | 120.1 | · | · | |
| EV / EBITDA | 135.0 | 154.7 | · | 152.3 | 149.4 | 148.2 | · | 170.5 | 150.6 | 159.4 | · | 136.0 | 158.5 | 146.5 | · | 118.7 | |
| EV / FCF | · | 160.7 | · | · | · | 193.1 | · | · | · | 93.8 | · | · | · | 182.8 | · | · | |
| EV / Revenue | 1.7 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.1 | 1.8 | 1.9 | · | 1.7 | 2.0 | 1.8 | · | 1.5 | |
| Earnings Yield | 7.3% | 5.8% | · | 5.9% | 6.2% | 6.6% | · | 5.0% | 6.1% | 5.7% | · | 6.9% | 5.6% | 6.4% | · | 10.3% | |
| Payout Ratio | · | 11.3% | · | · | · | 11.2% | · | · | · | 11.6% | · | · | · | 12.8% | · | · |
القوائم المالية قائمة الدخل، الميزانية العمومية، التدفقات النقدية — سنويًا، آخر 5 سنوات
قائمة الدخل
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| الإيرادات | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B |
| صافي الدخل | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B |
| EPS المخفف | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 |
الميزانية العمومية
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| الدين / حقوق الملكية | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 |
| النسبة الحالية | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 |
| النسبة السريعة | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 |
التدفق النقدي
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| التدفق النقدي الحر | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B |
آخر الأخبار أحدث العناوين التي تذكر هذه الشركة
- Could HCA Healthcare, Inc. (HCA) Stock Rebound After Guidance Cuts and Payer Pressure?
- Bernstein Remains Bullish On HCA Healthcare (HCA); Projects EBITDA Growth Of 2.8% and 4.6% in 2026 And 2027
- HCA Healthcare (HCA) Reports Q1 2026 Financial Growth With $19.1B in Revenue
- نشاط خيارات ملحوظ يوم الخميس: HCA، HRTG، ZM
- استراتيجية تمويل HCA Healthcare (HCA) تتوسع – إليك كيف
- HCA Healthcare تتجاوز تقديرات أرباح الربع السنوي مع زيادة الطلب على الرعاية الطبية
مقاييسي قائمة المراقبة الشخصية الخاصة بك — صفوف مختارة من الأساسيات الكاملة
اختر المقاييس التي تهمك — انقر فوق علامة ➕ بجوار أي صف في الأساسيات الكاملة أعلاه.
يتم حفظ اختيارك ويتبعك عبر جميع الأسهم.
الملاك المؤسسيون (13F) 1486 مقدمي إقرار · $39.4B إجمالي · حتى تاريخ 30 يونيو، 2026
المؤسسات التي تبلغ عن حيازتها لهذا السهم في نموذج SEC 13F ربع السنوي الخاص بها. المراكز الطويلة فقط؛ قد يظهر مقدم واحد مرتين لأرجل خيارات منفصلة. الأرجل الكبيرة المتعاكسة من خيارات البيع/الشراء تعكس عادةً صناعة السوق أو المخزون المتحوط، وليس القناعة الاتجاهية.
| مراكز جديدة | المراكز الخارجة | زيادة | انخفض | صافي التغير في الأسهم |
|---|---|---|---|---|
| 128 (-51 مقابل الربع السابق) | 174 (+70 مقابل الربع السابق) | 450 (-30 مقابل الربع السابق) | 555 (-4 مقابل الربع السابق) | +16.3M |
مقارنة بـ Q1 2026. المواعيد النهائية لتقديم إقرارات نموذج 13F لهيئة الأوراق المالية والبورصات (SEC) هي في غضون 45 يومًا من نهاية الربع بالإضافة إلى فترة سماح قصيرة للمقدمين المتأخرين — يتم تخطي الأرباع التي لا تزال ضمن هذه النافذة لصالح أحدث زوج تم الإبلاغ عنه بالكامل.
| مؤسسة | القيمة | الأسهم | % من 13F المتتبعة | النوع |
|---|---|---|---|---|
| VANGUARD GROUP INC | $6118113464 | 13104814 | 15,52% | الأسهم |
| VANGUARD CAPITAL MANAGEMENT LLC | $3954150533 | 10141708 | 10,03% | الأسهم |
| Sanders Capital, LLC | $3442060818 | 8828287 | 8,73% | الأسهم |
| STATE STREET CORP | $2912102056 | 7469035 | 7,39% | الأسهم |
| WELLINGTON MANAGEMENT GROUP LLP | $1750298867 | 4489212 | 4,44% | الأسهم |
| GEODE CAPITAL MANAGEMENT, LLC | $1225259672 | 3159159 | 3,11% | الأسهم |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1057704509 | 2712828 | 2,68% | الأسهم |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $861456107 | 2209485 | 2,19% | الأسهم |
| NORGES BANK | $836457140 | 2145367 | 2,12% | الأسهم |
| Capital World Investors | $770864224 | 1977121 | 1,96% | الأسهم |
| Capital International Investors | $747403041 | 1916947 | 1,90% | الأسهم |
| Crake Asset Management LLP | $449072183 | 1151792 | 1,14% | الأسهم |
| Metropolis Capital Ltd | $430915307 | 910564 | 1,09% | الأسهم |
| Darsana Capital Partners LP | $428879000 | 1100000 | 1,09% | الأسهم |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $414533777 | 1063207 | 1,05% | الأسهم |
| Life Cycle Investment Partners Ltd | $355737196 | 912404 | 0,90% | الأسهم |
| VANGUARD FIDUCIARY TRUST CO | $339685814 | 871235 | 0,86% | الأسهم |
| FMR LLC | $325199295 | 834080 | 0,83% | الأسهم |
| BARCLAYS PLC | $299888573 | 769162 | 0,76% | الأسهم |
| LYRICAL ASSET MANAGEMENT LP | $255015742 | 654071 | 0,65% | الأسهم |
| BlackRock, Inc. | $240062291 | 615718 | 0,61% | الأسهم |
| ROYAL LONDON ASSET MANAGEMENT LTD | $235649908 | 604401 | 0,60% | الأسهم |
| National Pension Service | $230650346 | 591578 | 0,59% | الأسهم |
| NORDEA INVESTMENT MANAGEMENT AB | $230189125 | 594466 | 0,58% | الأسهم |
| GOLDMAN SACHS GROUP INC | $209775669 | 538038 | 0,53% | الأسهم |
| Gobi Capital LLC | $195742325 | 502045 | 0,50% | الأسهم |
| Cryder Capital Partners LLP | $194561738 | 499017 | 0,49% | الأسهم |
| Swiss National Bank | $172097446 | 441400 | 0,44% | الأسهم |
| AustralianSuper Pty Ltd | $159635782 | 409438 | 0,41% | الأسهم |
| Consulta Ltd | $155956000 | 400000 | 0,40% | الأسهم |
| LEE DANNER & BASS INC | $152150679 | 390240 | 0,39% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $151472265 | 388500 | 0,38% | عقد خيار الشراء |
| Mitsubishi UFJ Asset Management Co., Ltd. | $147943761 | 379450 | 0,38% | الأسهم |
| DIMENSIONAL FUND ADVISORS LP | $139697405 | 358300 | 0,35% | الأسهم |
| Vanguard Global Advisers, LLC | $136962509 | 351285 | 0,35% | الأسهم |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $134838505 | 288820 | 0,34% | الأسهم |
| ALLIANCEBERNSTEIN L.P. | $134459788 | 284126 | 0,34% | الأسهم |
| Sumitomo Mitsui Trust Group, Inc. | $132794974 | 340596 | 0,34% | الأسهم |
| TD Asset Management Inc | $131847152 | 338165 | 0,33% | الأسهم |
| Legal & General Group Plc | $127805162 | 327798 | 0,32% | الأسهم |
| California Public Employees Retirement System | $124133958 | 318382 | 0,31% | الأسهم |
| LAZARD ASSET MANAGEMENT LLC | $120619879 | 309369 | 0,31% | الأسهم |
| JANE STREET GROUP, LLC | $119540274 | 306600 | 0,30% | عقد خيار الشراء |
| VANGUARD ASSET MANAGEMENT, Ltd | $116069863 | 297699 | 0,29% | الأسهم |
| CAPTRUST FINANCIAL ADVISORS | $114741071 | 294291 | 0,29% | الأسهم |
| ANTIPODES PARTNERS Ltd | $113045096 | 289941 | 0,29% | الأسهم |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $109718328 | 231845 | 0,28% | الأسهم |
| CITADEL ADVISORS LLC | $105660190 | 271000 | 0,27% | عقد خيار الشراء |
| RHUMBLINE ADVISERS | $97580413 | 250277 | 0,25% | الأسهم |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | $97026076 | 248855 | 0,25% | الأسهم |
| MACKENZIE FINANCIAL CORP | $93597383 | 240061 | 0,24% | الأسهم |
| BloombergSen Inc. | $93160317 | 238940 | 0,24% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $92247974 | 236600 | 0,23% | عقد خيار البيع |
| Brandywine Global Investment Management, LLC | $89380814 | 191451 | 0,23% | الأسهم |
| BANK OF AMERICA CORP /DE/ | $89069981 | 228449 | 0,23% | الأسهم |
| NEUBERGER BERMAN GROUP LLC | $85926216 | 220386 | 0,22% | الأسهم |
| MILFORD FUNDS LTD | $82165029 | 210739 | 0,21% | الأسهم |
| Bridgewater Associates, LP | $79227208 | 203204 | 0,20% | الأسهم |
| Prana Capital Management, LP | $75552494 | 193779 | 0,19% | الأسهم |
| DANSKE BANK A/S | $73238497 | 187844 | 0,19% | الأسهم |
| FRANKLIN RESOURCES INC | $70965828 | 182015 | 0,18% | الأسهم |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $70445715 | 180681 | 0,18% | الأسهم |
| Quantinno Capital Management LP | $70407055 | 180581 | 0,18% | الأسهم |
| ARGENT CAPITAL MANAGEMENT LLC | $69149681 | 177357 | 0,18% | الأسهم |
| Retirement Systems of Alabama | $68081812 | 174618 | 0,17% | الأسهم |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $66167842 | 169709 | 0,17% | الأسهم |
| BNP PARIBAS FINANCIAL MARKETS | $64793090 | 166183 | 0,16% | الأسهم |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $64665206 | 165855 | 0,16% | الأسهم |
| HSBC HOLDINGS PLC | $64431534 | 165332 | 0,16% | الأسهم |
| AVIVA PLC | $64264789 | 164828 | 0,16% | الأسهم |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $64194533 | 135649 | 0,16% | الأسهم |
| SEB Asset Management AB | $63257255 | 162244 | 0,16% | الأسهم |
| TODD ASSET MANAGEMENT LLC | $62567208 | 160474 | 0,16% | الأسهم |
| Swedbank AB | $62528998 | 160376 | 0,16% | الأسهم |
| W1M Investment Management Ltd | $61247490 | 143647 | 0,16% | الأسهم |
| HARRIS ASSOCIATES L P | $60080879 | 154097 | 0,15% | الأسهم |
| Ensign Peak Advisors, Inc | $58372381 | 149715 | 0,15% | الأسهم |
| NEW YORK STATE COMMON RETIREMENT FUND | $57747778 | 148113 | 0,15% | الأسهم |
| CITADEL ADVISORS LLC | $57235852 | 146800 | 0,15% | عقد خيار البيع |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $57160993 | 146800 | 0,15% | الأسهم |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $56512217 | 144944 | 0,14% | الأسهم |
| Pictet Asset Management Holding SA | $52147803 | 133739 | 0,13% | الأسهم |
| VICTORY CAPITAL MANAGEMENT INC | $50752761 | 130172 | 0,13% | الأسهم |
| Pentwater Capital Management LP | $50685700 | 130000 | 0,13% | الأسهم |
| D. E. Shaw & Co., Inc. | $50554307 | 129663 | 0,13% | الأسهم |
| APG Asset Management N.V. | $50368550 | 147699 | 0,13% | الأسهم |
| AMF Tjanstepension AB | $50355853 | 129154 | 0,13% | الأسهم |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $50349225 | 129137 | 0,13% | الأسهم |
| EQUITABLE TRUST CO | $49147974 | 126056 | 0,12% | الأسهم |
| ENVESTNET ASSET MANAGEMENT INC | $48919124 | 125469 | 0,12% | الأسهم |
| CANADA PENSION PLAN INVESTMENT BOARD | $48197812 | 123619 | 0,12% | الأسهم |
| AMERICAN CENTURY COMPANIES INC | $47460140 | 121727 | 0,12% | الأسهم |
| OpenArc Corporate Advisory, LLC | $47210610 | 121087 | 0,12% | الأسهم |
| L1 Capital International Pty Ltd | $46121648 | 118294 | 0,12% | الأسهم |
| FIRST TRUST ADVISORS LP | $44251579 | 113498 | 0,11% | الأسهم |
| PFA Pension, Forsikringsaktieselskab | $44046098 | 112971 | 0,11% | الأسهم |
| United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund | $43830264 | 112417 | 0,11% | الأسهم |
| EP Wealth Advisors, LLC | $43287826 | 111026 | 0,11% | الأسهم |
| WOLVERINE TRADING, LLC | $42597104 | 101200 | 0,11% | عقد خيار الشراء |
| MERCER GLOBAL ADVISORS INC /ADV | $42302070 | 108497 | 0,11% | الأسهم |
المطلعون على الشركة 91 من المطلعين · مسؤولون 54 · مديرون 31
| مطلع | الدور | آخر نشاط | الأسهم المملوكة | مشتريات 12 شهرًا | مبيعات 12 شهرًا | صافي 12 شهرًا |
|---|---|---|---|---|---|---|
| Samuel N Hazen | CEO | 10 فبراير، 2026 F | 64842 | 0 | 7 | $-21483290 |
| O'Boyle Michael P | President & CEO - Parallon | 26 فبراير، 2013 A | 21429 | 0 | 0 | $0 |
| Mike A Marks | EVP and CFO | 7 مايو، 2026 G | 46576 | 0 | 0 | $0 |
| Bill B Rutherford | CFO and EVP | 16 فبراير، 2024 F | 22251 | 0 | 0 | $0 |
| Russell K Harms | CFO - Central Group | 17 نوفمبر، 2006 D | 0 | 0 | 0 | $0 |
| Robert Samuel Hankins JR | CFO-Outpatient Services Group | 17 نوفمبر، 2006 D | 0 | 0 | 0 | $0 |
| Richard J Shallcross | CFO - Western Group | 17 نوفمبر، 2006 D | 0 | 0 | 0 | $0 |
| Jeffrey T Crudele | CFO-Eastern Division | 1 يوليو، 2005 F | 13865 | 0 | 0 | $0 |
| Erol R Akdamar | Group President | 12 نوفمبر، 2024 M | 6843 | 0 | 0 | $0 |
| Timothy M Mcmanus | Group President | 31 يوليو، 2024 M | 27008 | 0 | 0 | $0 |
| Richard A Hammett | Group President | 16 فبراير، 2024 F | 17936 | 0 | 0 | $0 |
| Charles J Hall | Group President | 11 نوفمبر، 2022 M | 202443 | 0 | 0 | $0 |
| Bruce A Moore JR | Group President - Service Line | 11 نوفمبر، 2022 S | 30807 | 0 | 0 | $0 |
| Paul W Rutledge | Group President | 31 ديسمبر، 2012 A | 335657 | 0 | 0 | $0 |
| Beverly B Wallace | President - Parallon | 2 نوفمبر، 2011 M | 144714 | 0 | 0 | $0 |
| Charles Robert Evans | President - Eastern Group | 26 يوليو، 2006 A | 62173 | 0 | 0 | $0 |
| Marilyn B Tavenner | President-Outpatient Svcs Grp | 27 أكتوبر، 2005 A | 26154 | 0 | 0 | $0 |
| Greg Roth | President-Ambulatory Surgery | 31 أكتوبر، 2004 D | 9029 | 0 | 0 | $0 |
| Jay Grinney | President-Eastern Group | 7 مايو، 2004 D | 24177 | 0 | 0 | $0 |
| Jon M Foster | EVP and COO | 10 فبراير، 2026 F | 23062 | 0 | 0 | $0 |
| Michael R Mcalevey | EVP & Chief Legal & Admin Off. | 13 فبراير، 2026 M | 8853 | 0 | 2 | $-2747520 |
| Jennifer Berres | SVP & Chief Human Res. Officer | 11 فبراير، 2026 S | 11993 | 0 | 2 | $-4126932 |
| Christopher F. Wyatt | SVP & Controller | 11 فبراير، 2026 S | 44379 | 0 | 1 | $-2020000 |
| Erica Rossitto | SVP & Chief Nurse Executive | 10 فبراير، 2026 F | 10407 | 0 | 0 | $0 |
| Michael S. Cuffe | EVP and Chief Clinical Officer | 10 فبراير، 2026 F | 32080 | 0 | 1 | $-747135 |
| Sammie S Mosier | SVP & Chief Nurse Executive | 13 فبراير، 2025 F | 11113 | 0 | 0 | $0 |
| Kathleen M Whalen | SVP & Chief Ethics Officer | 14 نوفمبر، 2024 S | 9454 | 0 | 0 | $0 |
| Phillip G Billington | SVP-Internal Audit Services | 12 نوفمبر، 2024 M | 52702 | 0 | 0 | $0 |
| Joseph A Sowell III | SVP; Chief Development Officer | 5 أغسطس، 2024 G | 18526 | 0 | 0 | $0 |
| Deborah M Reiner | SVP - Mktg. & Communications | 29 يوليو، 2024 S | 3510 | 0 | 0 | $0 |
| Kathryn A. Torres | SVP-Payer Contracting & Align. | 25 يوليو، 2024 S | 17755 | 0 | 0 | $0 |
| Jeffrey E. Cohen | SVP-Government Relations | 9 مايو، 2024 S | 5185 | 0 | 0 | $0 |
| Chad J Wasserman | SVP and CIO | 18 مارس، 2024 M | 1576 | 0 | 0 | $0 |
| Martin P. Paslick | SVP and CIO | 12 إبريل، 2023 M | 24643 | 0 | 0 | $0 |
| Jane D. Englebright | SVP and Chief Nursing Officer | 9 نوفمبر، 2021 S | 0 | 0 | 0 | $0 |
| Robert A Waterman | SVP & General Counsel | 5 مايو، 2021 S | 50062 | 0 | 0 | $0 |
| William J Morrow | SVP - Finance and Treasurer | 18 فبراير، 2021 F | 5578 | 0 | 0 | $0 |
| Sandra L. Morgan | SVP-Provider Relations | 18 فبراير، 2021 F | 10122 | 0 | 0 | $0 |
| Victor L Campbell | SVP-Government Affairs | 1 مايو، 2019 A | 194145 | 0 | 0 | $0 |
| John M Steele | SVP & Chief Human Res. Officer | 25 فبراير، 2019 M | 84157 | 0 | 0 | $0 |
| Milton R Johnson | Chairman | 25 فبراير، 2019 M | 881823 | 0 | 0 | $0 |
| Ravi S. Chari | SVP-Clinical Excellence | 25 فبراير، 2018 M | 7003 | 0 | 0 | $0 |
| Alan R Yuspeh | SVP & Chief Ethics Officer | 25 فبراير، 2018 M | 35546 | 0 | 0 | $0 |
| Joseph N Steakley | SVP-Internal Audit Services | 25 فبراير، 2018 M | 65199 | 0 | 0 | $0 |
| Jana Joustra Davis | SVP - Mktg. & Corp. Affairs | 23 مايو، 2017 M | 26378 | 0 | 0 | $0 |
| David Gwin Anderson | SVP - Finance | 7 نوفمبر، 2016 M | 110167 | 0 | 0 | $0 |
| Donald W Stinnett | SVP & Controller | 25 فبراير، 2016 A | 51965 | 0 | 0 | $0 |
| Noel B Williams | SVP and CIO | 16 مايو، 2012 M | 299030 | 0 | 0 | $0 |
| Jack O Bovender JR | Chairman | 6 أكتوبر، 2009 A | 188340 | 0 | 0 | $0 |
| Carl V George | SVP - Development | 27 فبراير، 2009 M | 13092 | 0 | 0 | $0 |
المطلعون من إيداعات SEC Form 3/4/5؛ صافي = سوق مفتوح فقط
الناشطون والمالكون بنسبة 5%+ 4 حيازات
المستثمرون الذين قدموا الجدول الزمني 13D لدى هيئة الأوراق المالية والبورصات — ملكية مستفيدة تزيد عن 5% مع نية التأثير على المُصدر (حصص الناشطين، حملات مجلس الإدارة، الاندماج والاستحواذ). يعرض كل صف أحدث حالة معروفة لمركز مقدم الطلب هذا.
| مقدم | مقدم | حصة | الحالة | الغرض | إيداع |
|---|---|---|---|---|---|
| Frisco Holding II, Hercules Holding II, Thomas F. Frist, Jr., Thomas F. Frist III, William R. Frist, Patricia F. Elcan | 10 فبراير، 2026 | 31,60% | إيداع أولي | — | SEC |
| 22 نوفمبر، 2006 | — | إيداع أولي | — | SEC | |
| Merrill Lynch Bank USA | 11 سبتمبر، 2006 | — | إيداع أولي | — | SEC |
| Frisco, Inc., Frisco Partners, Thomas F. Frist, Jr., Patricia Champion Frist, Patricia Frist Elcan, William Robert Frist, Thomas F. Frist III, Merrill Lynch Professional Clearing Corp., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Merrill Lynch Financial Markets, Inc., Merrill Lynch International, Merrill Lynch & Co., Inc., Merrill Lynch Trust Company, FSB, Citigroup Inc.*, Bank of America Corporation, NB Holdings Corporation, NationsBanc Montgomery Holdings Corporation, Banc of America Securities LLC | 4 أغسطس، 2006 | — | إيداع أولي | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ملكية صناديق المؤشرات المتداولة محتفظ بها بواسطة 207 صناديق مؤشرات متداولة
الوزن يعكس فقط ممتلكات الأسهم المباشرة (N-PORT)؛ قد تحتفظ الصناديق المضاعفة أو القائمة على المشتقات بتعرض إضافي للمقايضة غير معروض.
| صندوق | الوزن | الوحدات | حتى تاريخ | المصدر |
|---|---|---|---|---|
| IHF · iShares Trust | 4,67% | 141320 SH | 8 أغسطس، 2026 | يومي |
| BUL · Pacer Funds Trust | 3,91% | 11437 NS | 30 إبريل، 2026 | N-PORT |
| YALL · Tidal Trust I | 3,61% | 9261 NS | 31 مايو، 2026 | N-PORT |
| BWTG · ETF Opportunities Trust | 3,02% | 1646 NS | 31 مايو، 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 2,32% | 99335 SH | 8 أغسطس، 2026 | يومي |
| ABIG · EA Series Trust | 2,00% | 2938 NS | 29 مايو، 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,99% | 39985 NS | 30 إبريل، 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,67% | 31685 SH | 8 أغسطس، 2026 | يومي |
| COWZ · Pacer Funds Trust | 1,64% | 688264 NS | 30 إبريل، 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 1,64% | 1762 NS | 30 إبريل، 2026 | N-PORT |
| FEGE · RBB Fund Trust | 1,46% | 74706 NS | 31 مايو، 2026 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 1,39% | 60385 SH | 8 أغسطس، 2026 | يومي |
| RPG · Invesco Exchange-Traded Fund Trust | 1,30% | 63448 SH | 8 أغسطس، 2026 | يومي |
| TMFE · RBB Fund, Inc. | 1,29% | 2892 NS | 31 مايو، 2026 | N-PORT |
| AMID · EA Series Trust | 1,23% | 3402 NS | 29 مايو، 2026 | N-PORT |
| FCPI · FIDELITY COVINGTON TRUST | 1,15% | 7180 NS | 30 إبريل، 2026 | N-PORT |
| FMAG · FIDELITY COVINGTON TRUST | 1,12% | 6544 NS | 30 إبريل، 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 1,12% | 73639 NS | 30 إبريل، 2026 | N-PORT |
| SRHQ · Elevation Series Trust | 1,10% | 4883 NS | 30 إبريل، 2026 | N-PORT |
| IYH · iShares Trust | 0,99% | 89420 SH | 8 أغسطس، 2026 | يومي |
| NEAR · iShares U.S. ETF Trust | 0,99% | 48109000 SH | 8 أغسطس، 2026 | يومي |
| CURE · Direxion Shares ETF Trust | 0,98% | 3122 NS | 30 إبريل، 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,90% | 470451 SH | 8 أغسطس، 2026 | يومي |
| NFRA · FlexShares Trust | 0,88% | 62176 NS | 30 إبريل، 2026 | N-PORT |
| REVS · Columbia ETF Trust I | 0,87% | 5693 NS | 30 إبريل، 2026 | N-PORT |
| RXL · ProShares Trust | 0,86% | 1632 NS | 31 مايو، 2026 | N-PORT |
| DIVB · iShares Trust | 0,85% | 36806 SH | 8 أغسطس، 2026 | يومي |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,82% | 24078000 | 8 أغسطس، 2026 | يومي |
| LSEQ · Harbor ETF Trust | 0,81% | 285 NS | 30 إبريل، 2026 | N-PORT |
| IXJ · iShares Trust | 0,80% | 81465 SH | 8 أغسطس، 2026 | يومي |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0,76% | 26493000 | 8 أغسطس، 2026 | يومي |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,74% | 2335 SH | 8 أغسطس، 2026 | يومي |
| FTC · First Trust Exchange-Traded AlphaDE… | 0,73% | 21329 NS | 30 إبريل، 2026 | N-PORT |
| RFFC · ALPS ETF Trust | 0,68% | 533 NS | 31 مايو، 2026 | N-PORT |
| QUVU · Hartford Funds Exchange-Traded Trust | 0,68% | 2698 NS | 30 إبريل، 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,67% | 12075 SH | 8 أغسطس، 2026 | يومي |
| VCEB · VANGUARD WORLD FUND | 0,62% | 8146000 PA | 8 أغسطس، 2026 | يومي |
| FDMO · FIDELITY COVINGTON TRUST | 0,61% | 11771 NS | 30 إبريل، 2026 | N-PORT |
| RECS · Columbia ETF Trust I | 0,58% | 72768 NS | 30 إبريل، 2026 | N-PORT |
| AFLG · First Trust Exchange-Traded Fund VI… | 0,56% | 9664 NS | 31 مايو، 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0,55% | 11876 SH | 8 أغسطس، 2026 | يومي |
| VLLU · Harbor ETF Trust | 0,54% | 54 NS | 30 إبريل، 2026 | N-PORT |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,53% | 7404 NS | 30 إبريل، 2026 | N-PORT |
| WLDR · Two Roads Shared Trust | 0,51% | 844 NS | 30 إبريل، 2026 | N-PORT |
| VALQ · AMERICAN CENTURY ETF TRUST | 0,50% | 4620 NS | 31 مايو، 2026 | N-PORT |
| AKAF · ETF Series Solutions | 0,50% | 39 NS | 31 مايو، 2026 | N-PORT |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0,50% | 22679000 | 8 أغسطس، 2026 | يومي |
| ROUS · Lattice Strategies Trust | 0,47% | 6388 NS | 30 إبريل، 2026 | N-PORT |
| VCLT · VANGUARD SCOTTSDALE FUNDS | 0,46% | 54218000 PA | 8 أغسطس، 2026 | يومي |
| CGGR · Capital Group Growth ETF | 0,45% | 290273 NS | 31 مايو، 2026 | N-PORT |